Rocket Pharmaceuticals, Inc. (RCKT)
After hours:
| Previous close | 22.33 |
| Open | 22.22 |
| Bid | 22.41 x 100 |
| Ask | 22.49 x 200 |
| Day's range | 22.18 - 22.92 |
| 52-week range | 14.89 - 32.53 |
| Volume | |
| Avg. volume | 684,411 |
| Market cap | 2.037B |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.86 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 50.08 |
Business WireRocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
CRANBURY, N.J., May 10, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced longer-term data updates from its lentiviral (LV) vector hematology portfolio presented at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Data updates demonstrate the continued safety and efficacy of the Phase 1/2 pivotal stud
ZacksRocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Business WireRocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
CRANBURY, N.J., May 06, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.
